1. Background
2. Objectives
3. Patients and Methods
4. Results
| Age Group, y | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0-10 | 25.90 | 34.20 | 24.60 | 23.90 | 25.00 | 26.00 | 28.00 | 23.00 | 28.90 | 27.40 | 21.40 |
| 10-20 | 29.30 | 28.60 | 31.60 | 31.50 | 31.30 | 29.00 | 25.00 | 23.90 | 23.30 | 21.90 | 23.60 |
| 20-30 | 19.10 | 16.80 | 22.20 | 22.10 | 25.40 | 22.30 | 28.00 | 29.40 | 24.70 | 24.10 | 32.20 |
| 30-40 | 8.80 | 7.80 | 8.40 | 9.60 | 8.10 | 10.30 | 7.10 | 10.60 | 9.50 | 9.10 | 10.90 |
| 40-50 | 6.60 | 6.00 | 7.20 | 6.00 | 5.10 | 6.10 | 5.70 | 6.30 | 5.80 | 7.80 | 5.20 |
| 50-60 | 4.10 | 2.10 | 2.40 | 3.20 | 2.60 | 2.80 | 3.20 | 3.10 | 3.70 | 4.70 | 4.00 |
| 60-70 | 4.30 | 3.00 | 2.60 | 2.10 | 1.6 | 2.10 | 1.60 | 1.90 | 2.10 | 2.10 | 1.50 |
| 70-80 | 1.90 | 1.10 | 0.9 | 1.30 | 0.70 | 1 | 1.2 | 1.4 | 1.4 | 1.8 | 0.90 |
| 80-90 | - | 0.4 | 0.2 | 0.3 | 0.1 | 0.30 | 0.20 | 0.30 | 0.60 | 0.70 | 0.30 |
| 90-100 | - | - | - | 0 | 0 | 0 | - | 0.10 | 0.10 | 0 | - |
a Data are presented as No. (%).
| 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Face | 15.1 | 13.8 | 11.7 | 12.5 | 12 | 13.4 | 13 | 10.8 | 11.1 | 11.6 | 10.4 |
| Hands and feet | 1.9 | 1.3 | 1.1 | 1.4 | 1.3 | 1.6 | 1 | 1 | 1.7 | 0.9 | 1.6 |
| Hands and face | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.7 | 3.5 |
| Face, hands, and feet | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.4 | 1 |
| Feet | 22.9 | 23.6 | 27 | 25.1 | 24.7 | 23.2 | 24.6 | 24.4 | 22.6 | 19 | 27.2 |
| Hands | 30.6 | 30.6 | 35.1 | 32.4 | 34 | 33 | 31.7 | 34.7 | 32.2 | 25.9 | 31.2 |
| Hands and face | 5.7 | 5.8 | 4.1 | 4.4 | 4.2 | 4.9 | 4.1 | 4 | 5.5 | 4.3 | 0.1 |
| Hands, face, and feet | 0.5 | 3 | 1.2 | 1.5 | 1.5 | 1.5 | 2.1 | 1 | 1.9 | 0 | 0 |
| Hands and feet | 12.2 | 14.9 | 11.3 | 10.8 | 9.9 | 11.6 | 11.3 | 11 | 12.5 | 8.6 | 9.6 |
| Body | 11.1 | 7.2 | 8.5 | 11.8 | 12.2 | 10.7 | 12.2 | 13.1 | 12.4 | 7.9 | 14 |
a Data are presented as No. (%).
| 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tiran & Karvand | 8.8 | 11 | 17 | 22 | 11 | 0.58 | 0 | 23 | 22 | 5.8 | 20 |
| Khomeini-Shahr | 5.3 | 0.99 | 5.9 | 5.3 | 5.9 | 1.3 | 0 | 11 | 4.9 | 3.9 | 0 |
| Semirom | 0 | 0 | 0 | 0 | 0 | 4.2 | 0 | 0 | 5.6 | 2.8 | 4.2 |
| Falavarjan | 0 | 0 | 1.3 | 7 | 0 | 0.848 | 0 | 21.4 | 12 | 7.1 | 9.8 |
| Fereidan | 5.3 | 0.89 | 3.5 | 0.53 | 7.1 | 9.46 | 0 | 0 | 8.2 | 15 | 3.5 |
| Fereydon-shahr | 1.1 | 0 | 0 | 4.7 | 8.2 | 0 | 0 | 0 | 0 | 34 | 9.9 |
| Mobarake | 4.9 | 0 | 4.5 | 9.9 | 4.9 | 3.7 | 0 | 15 | 6 | 9.1 | 1.5 |
| Najaf abad | 1.74 | 4.5 | 0.33 | 8.3 | 7.5 | 4.3 | 0 | 11 | 7 | 6.3 | 3.6 |
| Shahreza | 5.6 | 0.99 | 0.49 | 0.33 | 5.9 | 1 | 0 | 29 | 24 | 12 | 19 |
| Golpayegan | 8.5 | 2.1 | 0 | 13 | 5.7 | 0 | 0 | 0 | 0 | 4.9 | 7.4 |
| Dahaghan | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 11 | 0 | 13 | 16 |
| Chadegan | 0 | 0 | 0 | 2.7 | 2.7 | 0 | 0 | 2.8 | 11 | 5.6 | 0 |
| Lenjan | 6.6 | 1.6 | 3.7 | 5.6 | 2.8 | 12.8 | 0 | 21.5 | 10 | 5.8 | 10 |
| Shahin shahr | 0 | 0 | 0 | 9.5 | 0 | 0 | 0 | 0 | 0 | 25 | 15 |
| Khansar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
a Data shows the prevalence of infection in 100000 people in each region.




